TSXV-Listed Quest PharmaTech's OncoQuest Publishes Two Reports Related to Oregovomab Phase 2 Clinical Trial "08:29 AM EDT, 03/24/2020 (MT Newswires) -- Quest PharmaTech (QPT.V) subsidiary, OncoQuest Inc, a privately held, cancer immunotherapy company today announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the company's lead investigational drug in frontline ovarian cancer.
The first report, in the journal Gynecologic Oncology, highlights the clinical results in the completed 97-patient randomized controlled multi-site study in which 47 patients were randomized to receive chemoimmunotherapy (with oregovomab) or standard chemotherapy (standard carboplatin and paclitaxel).
The study was conducted with a median of 42 months follow up and shows "highly statistically significant outcomes" for both progression-free and overall survival favoring the chemoimmunotherapy arm. The risk of progression and of death was reduced by more than 50% in the chemoimmunotherapy arm. S afety data shows that the addition of orgeovomab did not add incremental toxicity to chemotherapy, Quest added.
The second report published in Cancer Immunology, Immunotherapy, examined translational laboratory (from lab bench to bedside) outcomes from a subset of the Italian cohort of patients in the above described study. The report confirms that chemoimmunotherapy correlated with favorable clinical outcomes.
"The publication of our Phase II clinical results in peer reviewed journals validates the quality of the clinical data generated from our clinical study", said Dr. Madiyalakan, CEO of OncoQuest "We have discussed our Phase 2 results in an End of Phase 2 meeting with the FDA and based on those discussions are proceeding with our planned Phase 3 registration trial."
The company is currently planning to launch a Phase 3 trial in Q2 2020. The planned Phase 3 study is expected to enroll over 600 patients with newly diagnosed, advanced ovarian cancer globally."
glta
G1945V